Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$53.66 USD

53.66
22,196,871

-0.10 (-0.19%)

Updated Oct 3, 2024 09:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others

by Zacks Equity Research

Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.

Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q4 earnings and sales. Its 2023 financial outlook falls short of expectations. Stock down in pre-market trading.

Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $72.45 in the latest trading session, marking a -0.74% move from the prior day.

Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.

Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to Decline

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%

by Zacks Equity Research

Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $73.26, moving -1.2% from the previous trading session.

Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal

by Zacks Equity Research

Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.

bluebird (BLUE) Stock Dives on Public Offering of Common Stock

by Zacks Equity Research

bluebird (BLUE) to issue secondary shares, diluting its current shareholder base. The company plans to raise $120 million in gross proceeds from this issue.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $72.31 in the latest trading session, marking a -0.28% move from the prior day.

The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Honeywell, Sony, Airbnb and Republic Services

by Zacks Equity Research

Bristol-Myers Squibb, Honeywell, Sony, Airbnb and Republic Services are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Bristol-Myers Squibb, Honeywell International & Sony

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb Company (BMY), Honeywell International Inc. (HON) and Sony Group Corporation (SONY).

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $71.65, moving +0.9% from the previous trading session.

Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results

by Zacks Equity Research

Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?

by Zacks Equity Research

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $72.26, moving +0.43% from the previous trading session.